#For patients
Written for adults considering a peptide as part of their health management.
How Tesamorelin works: the mechanism
Tesamorelin binds GHRH receptors in the pituitary, triggers GH pulses, and raises IGF-1. Plain-English guide to the mechanism.
Tesamorelin side effects and safety data
The FDA label and phase-3 trials list injection site reactions, arthralgia, edema, and a threefold rise in new-onset dysglycemia. Here is what the data show.
What tirzepatide costs in Germany
Cash prices, GKV reimbursement rules, PKV coverage, and the AMNOG process that determines what Mounjaro costs in Germany in 2026.
What is Semax? A plain-English explainer
Semax is a synthetic neuropeptide licensed in Russia for stroke recovery and unapproved in the EU, UK, and US. Here is what the research actually shows.
Semaglutide side effects: what trials show
The STEP and SUSTAIN programmes documented semaglutide adverse events at scale. Here is what the data show, from GI effects to the thyroid boxed warning.
What is Semaglutide?
Semaglutide (Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist for type 2 diabetes and weight management. How it works and what the trials show.
Semaglutide in schizophrenia: HISTORI trial
Three randomised trials show semaglutide cuts weight and blood sugar in antipsychotic-treated patients without worsening psychiatric symptoms.
What is PT-141? A plain-English explainer
PT-141 (bremelanotide, brand name Vyleesi) is a melanocortin receptor agonist with one FDA-approved indication and no EU marketing authorisation.
Retatrutide: a plain-English explainer
Retatrutide is an investigational triple-receptor agonist: GLP-1, GIP, and glucagon. Phase 2 data showed up to 24% weight loss at 48 weeks. Not approved.
Semaglutide and weight in schizophrenia
A 24-week trial found semaglutide reduced body weight by 9.8% in people with schizophrenia on clozapine or olanzapine, with partial regain after stopping.
Semaglutide and the cost of CV benefit
A 2026 cost-effectiveness review places semaglutide, a GLP-1 agonist, in the moderate tier for preventing cardiovascular events. Here is what that means.
Semaglutide and heart risk: a 2026 review
A 2026 meta-analysis of 11 trials found semaglutide cut major cardiovascular events by about a third, similarly in people with and without diabetes.